{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T18:03:28Z","timestamp":1774289008106,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:00:00Z","timestamp":1586390400000},"content-version":"vor","delay-in-days":99,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2020]]},"DOI":"10.6061\/clinics\/2020\/e1566","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T14:20:47Z","timestamp":1586960447000},"page":"e1566","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5958-3181","authenticated-orcid":false,"given":"Wellington Fernandes","family":"da Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidiane In\u00eas","family":"da Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6637-3588","authenticated-orcid":false,"given":"Fernanda Salles","family":"Seguro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5298-9592","authenticated-orcid":false,"given":"Douglas Rafaele Almeida","family":"Silveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4751-1428","authenticated-orcid":false,"given":"Israel","family":"Bendit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6999-4109","authenticated-orcid":false,"given":"Valeria","family":"Buccheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9707-0579","authenticated-orcid":false,"given":"Elvira Deolinda Rodrigues Pereira","family":"Velloso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0094-619X","authenticated-orcid":false,"given":"Vanderson","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1567-4086","authenticated-orcid":false,"given":"Eduardo M","family":"Rego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.6061\/clinics\/2020\/e1566_bib1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1365-2141.2006.06314.x","article-title":"Guidelines on the management of acute myeloid leukaemia in adults","volume":"135","author":"Milligan","year":"2006","journal-title":"Br J Haematol"},{"issue":"6","key":"10.6061\/clinics\/2020\/e1566_bib2","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/ijc.30186","article-title":"Survival in patients with acute myeloblastic leukemia in Germany and the United States: Major differences in survival in young adults","volume":"139","author":"Pulte","year":"2016","journal-title":"Int J Cancer"},{"key":"10.6061\/clinics\/2020\/e1566_bib3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev"},{"issue":"2","key":"10.6061\/clinics\/2020\/e1566_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000486228","article-title":"Incidence, Survival, and Risk Factors for Adults with Acute Myeloid Leukemia Not Otherwise Specified and Acute Myeloid Leukemia with Recurrent Genetic Abnormalities: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database, 2001-2013","volume":"139","author":"Song","year":"2018","journal-title":"Acta Haematol"},{"key":"10.6061\/clinics\/2020\/e1566_bib5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.leukres.2017.07.005","article-title":"Evaluation of the European LeukemiaNet recommendations for predicting outcomes of patients with acute myeloid leukemia treated in low- and middle-income countries (LMIC): A Brazilian experience","volume":"60","author":"Benicio","year":"2017","journal-title":"Leuk Res"},{"issue":"3","key":"10.6061\/clinics\/2020\/e1566_bib6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","article-title":"How I treat refractory and early relapsed acute myeloid leukemia","volume":"126","author":"Thol","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.6061\/clinics\/2020\/e1566_bib7","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00277-018-3304-y","article-title":"Salvage regimens using conventional chemotherapy agents for relapsed\/refractory adult AML patients: a systematic literature review","volume":"97","author":"Meg\u00edas-Vericat","year":"2018","journal-title":"Ann Hematol"},{"issue":"6","key":"10.6061\/clinics\/2020\/e1566_bib8","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/leu.2017.23","article-title":"Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure","volume":"31","author":"Wattad","year":"2017","journal-title":"Leukemia"},{"key":"10.6061\/clinics\/2020\/e1566_bib9","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719827310","article-title":"Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia","volume":"10","author":"Short","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"10.6061\/clinics\/2020\/e1566_bib10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.leukres.2019.04.005","article-title":"Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis","volume":"81","author":"Stevens","year":"2019","journal-title":"Leuk Res"},{"issue":"8","key":"10.6061\/clinics\/2020\/e1566_bib11","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/sj.leu.2403846","article-title":"Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia","volume":"19","author":"Noguera","year":"2005","journal-title":"Leukemia"},{"issue":"2","key":"10.6061\/clinics\/2020\/e1566_bib12","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"1","key":"10.6061\/clinics\/2020\/e1566_bib13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.bjhh.2016.01.001","article-title":"Guidelines on the treatment of acute myeloid leukemia: Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular","volume":"38","author":"Bittencourt","year":"2016","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"24","key":"10.6061\/clinics\/2020\/e1566_bib14","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.6061\/clinics\/2020\/e1566_bib15","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1200\/JCO.1991.9.7.1210","article-title":"Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia","volume":"9","author":"Amadori","year":"1991","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.6061\/clinics\/2020\/e1566_bib16","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s002770050541","article-title":"Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML","volume":"78","author":"Steinmetz","year":"1999","journal-title":"Ann Hematol"},{"issue":"4","key":"10.6061\/clinics\/2020\/e1566_bib17","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","article-title":"Competing risk analysis using R: an easy guide for clinicians","volume":"40","author":"Scrucca","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.6061\/clinics\/2020\/e1566_bib18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"10.6061\/clinics\/2020\/e1566_bib19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.6061\/clinics\/2020\/e1566_bib20","doi-asserted-by":"crossref","first-page":"721","DOI":"10.6004\/jnccn.2019.0028","article-title":"Acute Myeloid Leukemia, Version 3.2019), NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Tallman","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"10.6061\/clinics\/2020\/e1566_bib21","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3324\/haematol.2016.148825","article-title":"An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation","volume":"101","author":"Ferguson","year":"2016","journal-title":"Haematologica"},{"issue":"2","key":"10.6061\/clinics\/2020\/e1566_bib22","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/bjh.14063","article-title":"Partial response after induction chemotherapy has clinical relevance in acute myeloid leukaemia","volume":"177","author":"Fleming","year":"2017","journal-title":"Br J Haematol"},{"issue":"6","key":"10.6061\/clinics\/2020\/e1566_bib23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/CCO.0000000000000404","article-title":"Relapsed\/refractory acute myeloid leukemia: any progress?","volume":"29","author":"Schlenk","year":"2017","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"10.6061\/clinics\/2020\/e1566_bib24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11864-017-0456-2","article-title":"Treatment of Relapsed\/Refractory Acute Myeloid Leukemia","volume":"18","author":"Bose","year":"2017","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"10.6061\/clinics\/2020\/e1566_bib25","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1080\/10428194.2016.1235274","article-title":"Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML)","volume":"58","author":"Fridle","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.6061\/clinics\/2020\/e1566_bib26","first-page":"549","article-title":"Mitoxantrone, etoposide and intermediate-dose Ara-C (MEC): an effective regimen for poor risk acute myeloid leukemia","volume":"7","author":"Spadea","year":"1993","journal-title":"Leukemia"},{"issue":"4","key":"10.6061\/clinics\/2020\/e1566_bib27","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1080\/10428194.2018.1508670","article-title":"FLAG salvage therapy combined with idarubicin in relapsed\/refractory acute myeloid leukemia","volume":"60","author":"Westhus","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.6061\/clinics\/2020\/e1566_bib28","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/oxfordjournals.annonc.a010796","article-title":"Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience","volume":"7","author":"Vignetti","year":"1996","journal-title":"Ann Oncol"},{"issue":"4","key":"10.6061\/clinics\/2020\/e1566_bib29","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s12185-019-02606-0","article-title":"Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia","volume":"109","author":"Hatsumi","year":"2019","journal-title":"Int J Hematol"},{"issue":"6","key":"10.6061\/clinics\/2020\/e1566_bib30","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s12185-012-1192-9","article-title":"Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy","volume":"96","author":"McLaughlin","year":"2012","journal-title":"Int J Hematol"},{"issue":"6","key":"10.6061\/clinics\/2020\/e1566_bib31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1590\/S1516-31802000000600005","article-title":"Conventional chemotherapy for acute myeloid leukemia: a Brazilian experience","volume":"118","author":"Pagnano","year":"2000","journal-title":"Sao Paulo Med J"},{"issue":"8","key":"10.6061\/clinics\/2020\/e1566_bib32","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1080\/10428190600627055","article-title":"De novo acute myeloid leukemia in adults younger than 60 years of age: socioeconomic aspects and treatment results in a Brazilian university center","volume":"47","author":"Fagundes","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.6061\/clinics\/2020\/e1566_bib33","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/j.clml.2018.03.001","article-title":"Treating Adult Acute Lymphoblastic Leukemia n Brazil\u2014Increased Early Mortality Using a German Multicenter Acute Lymphoblastic Leukemia-based regimen","volume":"18","author":"Fernandes da Silva","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.6061\/clinics\/2020\/e1566_bib34","first-page":"130","article-title":"The treatment of acute myeloid leukemia in Brazil: progress and obstacles","volume":"80","author":"Pulcheri","year":"1995","journal-title":"Haematologica"},{"issue":"7","key":"10.6061\/clinics\/2020\/e1566_bib35","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1182\/blood-2009-09-242859","article-title":"FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML","volume":"115","author":"Pratz","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.6061\/clinics\/2020\/e1566_bib36","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/leu.2011.25","article-title":"A new Leukemia Prognostic Scoring System for refractory\/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study","volume":"25","author":"Chevallier","year":"2011","journal-title":"Leukemia"},{"issue":"5","key":"10.6061\/clinics\/2020\/e1566_bib37","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/bjh.14107","article-title":"A prognostic model for survival after salvage treatment with FLAG-Ida +\/\u2212 gemtuzumab-ozogamicine in adult patients with refractory\/relapsed acute myeloid leukaemia","volume":"174","author":"Bergua","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"10.6061\/clinics\/2020\/e1566_bib38","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/leu.2017.22","article-title":"Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia","volume":"31","author":"Schlenk","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"10.6061\/clinics\/2020\/e1566_bib39","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1200\/JCO.2005.06.027","article-title":"Prognostic index for adult patients with acute myeloid leukemia in first relapse","volume":"23","author":"Breems","year":"2005","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.6061\/clinics\/2020\/e1566err","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000}}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222003106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222003106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T21:01:23Z","timestamp":1658005283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222003106"},"secondary":[{"URL":"https:\/\/www.clinicsjournal.com\/article\/salvage-treatment-for-refractory-or-relapsed-acute-myeloid-leukemia-a-10-year-single-center-experience\/","label":"CLINICS"},{"URL":"https:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1807-59322020000100227&lng=en&nrm=isso","label":"SCIELO"},{"URL":"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7134553\/","label":"PMC"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":39,"alternative-id":["S1807593222003106"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2020\/e1566","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"article-number":"e1566"}}